ASCO 2024 | Insights into the future of AKT inhibitors combination with chemotherapies for aTNBC

Maria Gion • 2 Jun 2024

ASCO 2024

Breast Cancer Eribulin

Maria Gion, MD, Ramón y Cajal University Hospital, Madrid, Spain, discusses the influence of recent trials for the combination of AKT inhibitors with chemotherapies on the treatment landscape for patients with advanced triple-negative breast cancer (aTNBC). Dr Gion highlights that, whilst results are promising, bigger trials combining eribulin or other drugs with AKT inhibitors are needed to say whether this could become a standard treatment or how it will fit in treatment sequencing. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – AstraZeneca; Gilead Sciences
Speakers’ Bureau – AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses – AstraZeneca; Pfizer; Roche